- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Public Companies
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Insights 13 results
Client Alert
February 17, 2021
Enforcing the Level Playing Field in the EU-UK Trade and Cooperation Agreement
Client Alert
November 30, 2020
Europe – Towards a More Harmonized Market for CBD?
Client Alert
October 26, 2020
France - Trial Period for Medical Use of Cannabis-Based Products
Client Alert
October 5, 2020
EUROPE – The General Court Limits the Scope of “Satisfactory Methods” That Must Be Compared for Orphan Drug Designation
Client Alert
September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations
Client Alert
September 10, 2020
EUROPE – Are Revisions of the Orphan Drug Regulation and Adoption of a Regulation on “Unmet Medical Needs” on the Horizon
Client Alert
August 24, 2020
France – Thresholds for Prior Authorization of Agreements with Healthcare Professionals and for Benefits of Low Value are Finally Out
Client Alert
Client Alert
April 24, 2020
One More Year: EU Medical Device Regulation Fully Applies on May 26, 2021
Client Alert
April 17, 2020
Europe Update – Life Sciences Products and COVID-19: From Clinical Trials to Regulatory Flexibility
Client Alert
March 23, 2020
U.S. and EU Regulators and Institutions Issue Guidance on Clinical Trial Conduct during COVID-19 Pandemic
Client Alert
February 11, 2020
The UK Begins Consultations to Inform "The UK Global Tariff", its New WTO Tariff Schedule